VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | MOMENTUM: momelotinib vs danazol in myelofibrosis

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, gives an update on the Phase III MOMENTUM study which is investigating momelotinib versus danazol in patients with myelofibrosis who have failed JAK inhibition and are transfusion-dependent and anemic. The study aims to improve spleen symptoms and anemia. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Ruben Mesa, MD, has participated in a consultancy role with Novartis, Sierra Onc, LaJolla, Pharma and Constellation; and has received research support from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior, CTI and Constellation.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter